Leukaemia update. Part 1: Diagnosis and management

BMJ (Online)

Volumn 346, Issue 7902, 2013, Pages

  Grigoropoulos, Nicholas F ^a   Petter, Roger ^b   Van'T Veer, Mars B ^c   Scott, Mike A ^c   Follows, George A ^c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b Linton Health Centre   (United Kingdom)

^c CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; IDARUBICIN; IMATINIB; RETINOIC ACID; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; BLOOD CELL COUNT; BLOOD EXAMINATION; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG RESPONSE; HUMAN; LEUKEMIA; LEUKEMIA REMISSION; LEUKOCYTOSIS; MANAGED CARE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME; GREAT BRITAIN;

ANTINEOPLASTIC AGENTS; GREAT BRITAIN; HUMANS; LEUKEMIA;

EID: 84876126412     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f1660     Document Type: Review

References (18)

1. Cancer Research UK. Leukaemia incidence statistics. www.cancerresearchuk. org/cancer-info/cancerstats/types/leukaemia/incidence/.
2. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pilleri SA, Stein H, et al, eds. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. IARC Press, 2008.
3. Grove CS, Follows GA, Erber WN. Incidental finding of lymphocytosis in an asymptomatic patient. BMJ 2009;338:b2119.
4. CLL Trialists' Collaborative Group. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. J Natl Cancer Inst 1999;91:861-8.
5. Oscier D, Dearden C, Erem E, Fegan C, Follows G, Hillmen P, et al. Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. Br J Haematol 2012;159:541-64.
6. Else M, Cocks K, Crofts S, Wade R, Richards SM, Catovsky D, et al. Quality of life in chronic lymphocytic leukemia: 5-year results from the multicenter randomized LRF CLL4 trial. Leuk Lymphoma 2012;53:1289-98.
7. Pettitt AR, Jackson R, Carruthers S, Dodd J, Dodd S, Oates M, et al. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial. J Clin Oncol 2012;30:1647-55.
8. National Institute for Health and Clinical Excellence. Bendamustine for the first-line treatment of chronic lymphocytic leukaemia. 2011. www.nice.org.uk/nicemedia/live/13343/53180/53180.pdf.
9. Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009;23:1054-61.
10. Ng KP, Hillmer AM, Chuah CT, Juan WC, Ko TK, Teo AS, et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med 2012;18:521-8.
11. National Institute for Health and Clinical Excellence. Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML) (part review of NICE technology appraisal guidance 70) and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance. 2012. www.nice.org.uk/nicemedia/live/13645/ 57823/57823.pdf.
12. Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012;367:2075-88.
13. Hann I, Vora A, Richards S, Hill F, Gibson B, Lilleyman J, et al. Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: results from MRC UKALL XI and MRC ALL97 randomised trials. UK Medical Research Council's working party on childhood leukaemia. Leukemia 2000;14:356-63. (Pubitemid 30142855)
14. Mitchell C, Hall G, Clarke RT. Acute leukaemia in children: diagnosis and management. BMJ 2009;338:b2285.
15. Sive JI, Buck G, Fielding A, Lazarus HM, Litzow MR, Luger S, et al. Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial. Br J Haematol 2012;157:463-71.
16. Roboz GJ. Current treatment of acute myeloid leukemia. Curr Opin Oncol 2012;24:711-9.
17. Sanz MA, Montesinos P, Vellenga E, Rayon C, de la Serna J, Parody R, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. Blood 2008;112:3130-4.
18. Burnett AK, Hills RK, Milligan D, Kjeldsen L, Kell J, Russell NH, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol 2011;29:369-77.